Armstrong Anne C, Eaton David, Ewing Joanne C
Department of Medical Oncology, Paterson Institute of Cancer Research, Christie Hospital NHS Trust, Manchester, UK.
Expert Rev Vaccines. 2002 Oct;1(3):303-16. doi: 10.1586/14760584.1.3.303.
Observations that cells of the immune system are able to kill tumor cells both in vitro and in animal models have provided a compelling rationale for pursuit of a strategy whereby immune cells are administered as a therapeutic vaccine to patients with cancer. The successful outcome of this approach depends upon the ability to deliver this therapy in a manner in which a potent immune response is elicited. By harnessing the capacity of dendritic cells that are pivotal in priming the immune response and using gene therapy approaches to optimise the immune response, this may ultimately prove efficacious in the management of human cancer. Promising reports from recent clinical trials suggest that this may well be a realistic goal.
免疫系统细胞能够在体外和动物模型中杀死肿瘤细胞，这一观察结果为采用将免疫细胞作为治疗性疫苗给予癌症患者的策略提供了令人信服的理论依据。这种方法的成功结果取决于能否以引发强大免疫反应的方式提供这种治疗。通过利用在启动免疫反应中起关键作用的树突状细胞的能力，并使用基因治疗方法来优化免疫反应，这最终可能在人类癌症的治疗中证明是有效的。最近临床试验的有前景的报告表明，这很可能是一个现实的目标。
